Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed (INSM) is holding its fifth annual Global Day of Good on September 16, 2026, a company-wide day of service involving employees worldwide.
The 2026 event is described as the largest yet, with more than 1,350 employees across the U.S., Europe, and Japan participating in 50 activities that benefit over 50 nonprofit organizations. Volunteer efforts focus on health, education, and human services, ranging from STEM kit assembly and food bank support to environmental cleanups, care packages for children with serious diseases, book translation, student wellbeing workshops, and bicycle refurbishment. Over five years, employees have logged about 15,000 volunteer hours through this initiative.
Insmed (INSM) granted equity inducement awards to 128 new employees under its 2025 Inducement Plan, designed to comply with Nasdaq Listing Rule 5635(c)(4).
Effective August 31, 2026, the employees received a total of 115,320 restricted stock units and options to purchase an aggregate 5,560 shares of Insmed common stock at an exercise price of $121.82 per share, equal to the closing trading price on the grant date. The restricted stock units vest over four years in equal 25% annual installments, starting on the first anniversary of the first day of the month following the grant date, subject to continued service.
The stock options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first such anniversary and 12.5% vesting every six months thereafter through the fourth anniversary, also contingent on continued employment.
Insmed (INSM) will present five abstracts from its respiratory portfolio at the European Respiratory Society Congress 2026 in Barcelona from Sept. 5–9, 2026.
Featured work includes a late-breaking Phase 3b ENCORE analysis of 12 months of ARIKAYCE® plus multidrug therapy in adults with newly diagnosed Mycobacterium avium complex (MAC) lung infection who were antibiotic‑naïve. Additional presentations cover a COMPERA 2.0 risk assessment post hoc analysis of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension, post hoc Phase 3 ASPEN data on BRINSUPRI® (brensocatib) in non-cystic fibrosis bronchiectasis (NCFB) with prior nontuberculous mycobacterial infection, and studies on the psychosocial burden, treatment patterns, and healthcare resource use associated with bronchiectasis. The release also reiterates approved indications and extensive U.S. safety information for ARIKAYCE and BRINSUPRI, including a boxed warning for increased respiratory adverse reactions with ARIKAYCE.
Insmed (Nasdaq: INSM) announced that management will present at two September 2026 investor conferences in New York City: the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9 at 8:00 a.m. ET and the 24th Annual Morgan Stanley Global Healthcare Conference on September 14 at 2:35 p.m. ET. Live webcasts and 30-day archives will be available via Insmed's investor relations website.
Insmed (Nasdaq: INSM) announced that Japan’s Ministry of Health, Labour and Welfare has approved BRINSUPRI (brensocatib 25 mg), a once-daily oral treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients ≥12 years. BRINSUPRI is the first and only treatment approved for NCFB in Japan and is now authorized in the U.S., Europe, and Japan.
According to Insmed, approval is based on the Phase 3 ASPEN study, where brensocatib significantly reduced pulmonary exacerbations versus placebo over 52 weeks, prolonged time to first exacerbation, increased the proportion of exacerbation‑free patients, and was associated with lower lung function decline (FEV1). Brensocatib was generally well tolerated; common adverse events included COVID‑19, nasopharyngitis, cough, and headache.
Insmed (Nasdaq: INSM) reported second-quarter 2026 total revenues of $425.5 million, up 296% year over year, driven by U.S. BRINSUPRI® (brensocatib) launch. BRINSUPRI generated $309.2 million in Q2, growing 49% versus Q1 2026, while ARIKAYCE® revenues reached $116.3 million, an 8% increase versus Q2 2025.
The company recorded a Q2 2026 net loss of $13.2 million or $0.06 per share, markedly improved from a $321.7 million loss a year earlier, helped by a $99.8 million favorable change in contingent consideration liabilities. Operating expenses totaled $427.0 million, with R&D at $210.0 million and SG&A at $247.5 million, reflecting BRINSUPRI commercial investment and TPIP development.
As of June 30, 2026, Insmed held roughly $1.2 billion in cash, cash equivalents, and marketable securities. The company raised 2026 BRINSUPRI revenue guidance to $1.25–$1.40 billion, reiterated 2026 ARIKAYCE guidance of $450–$470 million, and increased combined peak revenue estimates for BRINSUPRI, TPIP, and ARIKAYCE to over $14 billion.
Insmed (Nasdaq: INSM) will release its second-quarter 2026 financial results on Thursday, August 6, 2026. Management will host a conference call for investors at 8:00 a.m. ET that day to discuss the results and provide a business update, with live access by phone and webcast.
Participants can join via U.S. dial-in (888) 210-2654 or international (646) 960-0278 using access code 7862189, or listen through the company website. A telephone replay will be available until August 13, 2026, and the webcast will be archived for 90 days in Insmed’s Investor Relations section.
Insmed (Nasdaq: INSM) reported positive 12-month results from its ongoing open-label extension study of once-daily treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH, WHO Group 1) who completed prior TPIP PAH studies.
Across TPIP Continued (N=60) and Placebo Crossed (N=31) groups, mean six-minute walk distance improved by approximately 56 and 54 meters, respectively, and NT-proBNP levels fell by about 60% (geometric mean ratios 0.40 and 0.41). WHO Functional Class I or II was reached by 78.3% and 80.6% of patients, with more than 25% in Functional Class I. Mean REVEAL Lite 2.0 score improved by 2.0 and 1.4 points, and about 65% of all patients achieved Refined Low Risk status, which is associated with a less than 5% estimated three-year mortality risk.
Once-daily TPIP was generally well tolerated up to 1,280 µg through Month 12. Among 91 patients, treatment-emergent adverse events occurred in 89.0%, serious events in 18.7%, severe events in 16.5%, and 7.7% discontinued due to events. Four deaths were reported, none considered related to TPIP. These findings support continued development, including the recently initiated Phase 3 PALM-PAH trial.
Insmed (Nasdaq: INSM) appointed Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective June 23, 2026. He will lead the Respiratory Therapeutic Area, report to CEO Will Lewis, and serve on the Executive Committee.
Butera brings more than 20 years of global commercial leadership from Johnson & Johnson, Novartis, Sandoz Biopharmaceuticals, McKinsey, Goldman Sachs, and the United Nations. According to Insmed, his experience supports the launch of BRINSUPRI, potential ARIKAYCE label expansion, and the TPIP development program.
Insmed (Nasdaq: INSM) granted inducement equity awards to 103 new employees under its 2025 Inducement Plan, intended to comply with Nasdaq Listing Rule 5635(c)(4).
On May 29, 2026, employees received 97,091 RSUs and options on 12,850 shares at an exercise price of $106.91, with four-year vesting schedules.